Voyager Therapeutics ROA 2014-2022 | VYGR

Current and historical return on assets (ROA) values for Voyager Therapeutics (VYGR) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Voyager Therapeutics ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-03-31 $-0.07B $0.22B -34.48%
2021-12-31 $-0.07B $0.19B -34.38%
2021-09-30 $-0.09B $0.19B -41.61%
2021-06-30 $0.02B $0.21B 7.35%
2021-03-31 $0.04B $0.24B 14.62%
2020-12-31 $0.04B $0.26B 12.85%
2020-09-30 $0.04B $0.27B 12.85%
2020-06-30 $-0.06B $0.30B -18.06%
2020-03-31 $-0.04B $0.32B -11.37%
2019-12-31 $-0.04B $0.36B -11.50%
2019-09-30 $-0.05B $0.38B -15.96%
2019-06-30 $-0.06B $0.39B -20.10%
2019-03-31 $-0.10B $0.41B -38.40%
2018-12-31 $-0.09B $0.18B -43.20%
2018-09-30 $-0.08B $0.20B -37.55%
2018-06-30 $-0.08B $0.22B -41.81%
2018-03-31 $-0.07B $0.24B -41.23%
2017-12-31 $-0.07B $0.18B -43.16%
2017-09-30 $-0.07B $0.14B -44.58%
2017-06-30 $-0.06B $0.16B -33.10%
2017-03-31 $-0.05B $0.18B -25.74%
2016-12-31 $-0.04B $0.19B -19.46%
2016-09-30 $-0.03B $0.20B -15.80%
2016-06-30 $-0.03B $0.21B -15.52%
2016-03-31 $-0.03B $0.22B -19.51%
2015-12-31 $-0.04B $0.23B -39.49%
2015-09-30 $-0.04B $0.17B -79.10%
2015-06-30 $-0.03B $0.00B -1163.64%
2015-03-31 $-0.03B $0.00B -1090.91%
2014-12-31 $-0.02B $0.01B -618.18%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.227B $0.037B
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.938B 9.97
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.718B 16.92
Biohaven Pharmaceutical Holding (BHVN) United States $10.276B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.817B 46.07
Emergent Biosolutions (EBS) United States $1.560B 6.68
Myovant Sciences (MYOV) United Kingdom $1.185B 0.00
Zymeworks (ZYME) Canada $0.306B 0.00
Gelesis Holdings (GLS) United States $0.112B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.090B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00